Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

Affiliations

¹ Department of Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland. andreas.gantenbein@zurzachcare.ch.
² Kopfwehzentrum Hirslanden, Zurich, Switzerland.
³ Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland.
⁴ Neurocentre, Luzerner Kantonsspital, Lucerne, Switzerland.
⁵ Center for Pain Medicine, Nottwil, Switzerland.
⁶ Department of Neurology, Spital Thun, Thun, Switzerland.
⁷ Department of Reproductive Endocrinology, University Hospital Zurich, Zurich, Switzerland.
⁸ Neurozentrum Bern, Bern, Switzerland.
⁹ Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
¹⁰ Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland.
¹¹ Private Practice, Sion, Switzerland.
¹² Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
¹³ Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
¹⁴ Department of Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland.
¹⁵ Novartis Pharma Schweiz AG, Rotkreuz, Switzerland.

Published Erratum

Andreas R Gantenbein et al. J Headache Pain. 2022.

. 2022 Dec 19;23(1):161.

doi: 10.1186/s10194-022-01530-9.

¹ Department of Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland. andreas.gantenbein@zurzachcare.ch.
² Kopfwehzentrum Hirslanden, Zurich, Switzerland.
³ Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland.
⁴ Neurocentre, Luzerner Kantonsspital, Lucerne, Switzerland.
⁵ Center for Pain Medicine, Nottwil, Switzerland.
⁶ Department of Neurology, Spital Thun, Thun, Switzerland.
⁷ Department of Reproductive Endocrinology, University Hospital Zurich, Zurich, Switzerland.
⁸ Neurozentrum Bern, Bern, Switzerland.
⁹ Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
¹⁰ Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland.
¹¹ Private Practice, Sion, Switzerland.
¹² Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
¹³ Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
¹⁴ Department of Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland.
¹⁵ Novartis Pharma Schweiz AG, Rotkreuz, Switzerland.

No abstract available

Figures

Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.
Gantenbein AR, Agosti R, Kamm CP, Landmann G, Meier N, Merki-Feld GS, Petersen JA, Pohl H, Ryvlin P, Schankin CJ, Viceic D, Zecca C, Schäfer E, Meyer I, Arzt ME. Gantenbein AR, et al. J Headache Pain. 2022 Nov 18;23(1):142. doi: 10.1186/s10194-022-01515-8. J Headache Pain. 2022. PMID: 36401172 Free PMC article.

1. Gantenbein AR, Agosti R, Kamm CP, et al. Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results. J Headache Pain. 2022;23:142. doi: 10.1186/s10194-022-01515-8. - DOI - PMC - PubMed